

About SK life science

SK Life Science, Inc. (SKLSI) is part of something bigger. Established in 1993 and located in Fair Lawn, New Jersey, SKLSI is committed to accelerating the development of next-generation treatments for disorders of the central nervous system (CNS). It is a U.S. subsidiary of SK Biopharmaceuticals, Co., Ltd. (SKBP), a company focused on discovery, development and commercialization of innovative medicines. Both SKLSI and SKBP are a part of SK Group, the second largest company in Korea and a global leader in the energy, chemical, semiconductor and telecommunications industries.

SKLSI is focused on the discovery and development of next-generation investigational drugs within multiple therapeutic categories—with the goal of changing what is possible in CNS treatment.

Our vision

By taking on the mysteries of the brain, we strive to make life better




SK life science
a subsidiary of SK biopharmaceuticals
Fair Lawn, NJ, USA



Our pipeline sets the stage for success in CNS

We have a pipeline of eight products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound in a Phase 3 global clinical trial for the potential treatment of epilepsy in adult patients.



Making a difference in epilepsy

Epilepsy is a condition of the brain causing seizures. Nearly 65 million people suffer from epilepsy worldwide, including more than 3.4 million people in the U.S.² The vast majority of epilepsy patients (60-70%) suffer from focal (POS) seizures.³

Having seizures is associated with debilitating and life-altering complications. Despite the availability of many anti-epileptic drugs, more than half of patients with epilepsy continue to have seizures, many with more than three seizures per year, according to the CDC.⁴

Epilepsy is associated with numerous complications, including:

- Risk of injury
- Unemployment and underemployment
- Dependency
- Depression and anxiety
- Cognitive impairment
- Poor quality of life
- Sudden unexplained death in epilepsy (SUDEP)

Our values define us

SK life science is defined by our values and driven by the unmet needs of patients, HCPs, caregivers, and the CNS community. Our values are more than words on a page – they are what you can expect from us:

- Empower excellence
- Be fully engaged
- Appreciate and recognize people
- Embody a pioneering spirit
- Always do the right thing
- Inspire happiness!

Leadership



Jeong Woo Cho, Ph.D.
President & Chief Executive Officer



Sebby Borriello
Vice President &
Chief Commercial Officer



Hong Wook Kim, Ph.D.
Vice President &
Chief Operating Officer



Marc Kamin, M.D.
Vice President &
Chief Medical Officer

Contact Us

General business
Info@sklsi.com

Media inquiries and PR
Media@sklsi.com

Strategic alliance and
partnership opportunities
Partnerships@sklsi.com

Follow Us



@SKlifescience



SK Life Science, Inc.

² CURE. What is epilepsy? <https://www.cureepilepsy.org/about-epilepsy/what-is-epilepsy>. Accessed Sept. 13, 2018.

³ The Epilepsies: Seizures, Syndromes and Management. <https://www.ncbi.nlm.nih.gov/books/NBK2605/> Accessed Oct. 23, 2018

⁴ Active Epilepsy and Seizure Control in Adults — United States, 2013 and 2015. CDC. April 20, 2018. <https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a1.htm>. Accessed Sept. 13, 2018.